<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="drug\PMC7216760\results\search\disease\results.xml">
  <result pre="courier ; font-style : italic;} ACS Infect DisACS Infect DisidaidcbcACS" exact="Infectious" post="Diseases2373-8227American Chemical Society doi: 10.1021/acsinfecdis.0c00224 : Viewpoint COVID-19: Living"/>
  <result pre="of MichiganUnited States[Â¶], Cairo UniversityEgypt *Email: neamati@med.umich.edu. epub: 2020-05-05acsinfecdis.0c00224received: 2020-04-20(C)" exact="American" post="Chemical Society, 2020This article is made available via the"/>
  <result pre="pathogenic agent responsible for coronavirus disease-2019 (COVID-19), a globally pandemic" exact="infectious disease." post="Due to its high virulence and the absence of"/>
  <result pre="pandemic infectious disease. Due to its high virulence and the" exact="absence of" post="immunity among the general population, SARS-CoV-2 has quickly spread"/>
  <result pre="and focus our research tools on what are considered â€œneglected" exact="infectious" post="diseasesâ€� and to prepare for future inevitable pandemics. This"/>
  <result pre="focused on speed to market, and novel agents against specific" exact="viral" post="targets as therapeutic interventions for COVID-19. As first reported"/>
  <result pre="As first reported in December 2019, a novel coronavirus, severe" exact="acute" post="respiratory syndrome coronavirus 2 (SARS-CoV-2), caused an outbreak of"/>
  <result pre="first reported in December 2019, a novel coronavirus, severe acute" exact="respiratory" post="syndrome coronavirus 2 (SARS-CoV-2), caused an outbreak of atypical"/>
  <result pre="reported in December 2019, a novel coronavirus, severe acute respiratory" exact="syndrome" post="coronavirus 2 (SARS-CoV-2), caused an outbreak of atypical pneumonia"/>
  <result pre="acute respiratory syndrome coronavirus 2 (SARS-CoV-2), caused an outbreak of" exact="atypical pneumonia" post="in Wuhan, China, that has since spread globally.1 The"/>
  <result pre="respiratory syndrome coronavirus 2 (SARS-CoV-2), caused an outbreak of atypical" exact="pneumonia" post="in Wuhan, China, that has since spread globally.1 The"/>
  <result pre="pneumonia in Wuhan, China, that has since spread globally.1 The" exact="disease" post="caused by this new virus has been named coronavirus"/>
  <result pre="HCoV-229E, while the beta-coronaviruses comprise HCoV-OC43, HCoV-HKU1, SARS, Middle East" exact="Respiratory" post="Syndrome virus (MERS), and SARS-CoV-2.2 The alpha-coronaviruses and HCoV-OC43"/>
  <result pre="while the beta-coronaviruses comprise HCoV-OC43, HCoV-HKU1, SARS, Middle East Respiratory" exact="Syndrome" post="virus (MERS), and SARS-CoV-2.2 The alpha-coronaviruses and HCoV-OC43 and"/>
  <result pre="more recent viruses appear to have been transmitted through an" exact="intermediate" post="host such as a civet, a small nocturnal mammal"/>
  <result pre="through an intermediate host such as a civet, a small" exact="nocturnal" post="mammal native to tropical Asia and Africa (SARS), a"/>
  <result pre="260,000 deaths, reflecting a âˆ¼6.8% case fatality rate. While the" exact="infection" post="fatality rate is currently unknown, and likely to be"/>
  <result pre="infection fatality rate is currently unknown, and likely to be" exact="lower" post="than the current case fatality rate, estimates suggest it"/>
  <result pre="it is close to 1%, or approximately 10 times the" exact="infection" post="fatality rate of seasonal influenza (flu), which is fatal"/>
  <result pre="end in sight due to its high virulence and the" exact="absence of" post="resistance among the general population. In general, all pandemics"/>
  <result pre="often not noticed early enough, leading to dissemination of the" exact="disease" post="before effective countermeasures can be initiated. During the second"/>
  <result pre="virus can mitigate this phase. In the third phase, the" exact="infection" post="rate curve will start to decrease until the disease"/>
  <result pre="the infection rate curve will start to decrease until the" exact="disease" post="becomes extinct or endemic. The kinetics of increase and"/>
  <result pre="The kinetics of increase and decrease in the rate of" exact="infections" post="can vary significantly between populations depending on the use"/>
  <result pre="expand and focus our research tools on these long neglected" exact="infectious diseases" post="and to prepare for future inevitable pandemics. Herein, we"/>
  <result pre="Coronaviridae family that also includes the highly fatal Middle East" exact="Respiratory" post="Syndrome virus (MERS) that appeared in 2012.7 SARS-CoV-2 enters"/>
  <result pre="family that also includes the highly fatal Middle East Respiratory" exact="Syndrome" post="virus (MERS) that appeared in 2012.7 SARS-CoV-2 enters cells"/>
  <result pre="cell entry by endocytosis.8 Upon membrane fusion and endocytosis, the" exact="viral" post="nucleocapsid with its genome payload is released into the"/>
  <result pre="membrane vesicles.9 These vesicles are perfect sanctuaries to protect the" exact="viral" post="genome and allow an efficient replication process to occur"/>
  <result pre="through a macromolecule complex called the replicationâ€&quot;transcription complex (RTC).10 The" exact="viral" post="genome is subsequently translated into viral polyproteins using the"/>
  <result pre="replicationâ€&quot;transcription complex (RTC).10 The viral genome is subsequently translated into" exact="viral" post="polyproteins using the host cell protein translation machinery, which"/>
  <result pre="translation machinery, which are then cleaved into structural and nonstructural" exact="viral" post="proteins by two viral proteases, Mpro and PLpro.11 This"/>
  <result pre="then cleaved into structural and nonstructural viral proteins by two" exact="viral" post="proteases, Mpro and PLpro.11 This step is followed by"/>
  <result pre="and PLpro.11 This step is followed by the assembly of" exact="viral" post="particles (virions) in the endoplasmic reticulum/golgi compartment.12 The packaged"/>
  <result pre="Clinical Course and Outcomes of COVID-19 SARS-CoV-2 likely binds to" exact="epithelial" post="cells in the nasal cavity during the asymptomatic state"/>
  <result pre="in the nasal cavity during the asymptomatic state of the" exact="disease" post="(initial 1â€&quot;2 days of infection) where there might be"/>
  <result pre="be some local propagation of the virus but with a" exact="limited" post="innate immune response. Within the next few days the"/>
  <result pre="limited innate immune response. Within the next few days the" exact="infection" post="starts in the upper airway and during this stage"/>
  <result pre="Within the next few days the infection starts in the" exact="upper" post="airway and during this stage the infection can be"/>
  <result pre="starts in the upper airway and during this stage the" exact="infection" post="can be detected by nasal swabs or sputum as"/>
  <result pre="patients show mild symptoms that are mostly restricted to the" exact="upper" post="and conducting airways.13 However, about 20% of infected patients"/>
  <result pre="about 20% of infected patients will progress to develop a" exact="lower" post="respiratory tract infection leading to hypoxia, and lung damage."/>
  <result pre="20% of infected patients will progress to develop a lower" exact="respiratory" post="tract infection leading to hypoxia, and lung damage. These"/>
  <result pre="infected patients will progress to develop a lower respiratory tract" exact="infection" post="leading to hypoxia, and lung damage. These patients are"/>
  <result pre="and lung damage. These patients are liable to succumb to" exact="acute" post="respiratory distress syndrome (ARDS), which is frequently fatal. Patients"/>
  <result pre="lung damage. These patients are liable to succumb to acute" exact="respiratory" post="distress syndrome (ARDS), which is frequently fatal. Patients with"/>
  <result pre="These patients are liable to succumb to acute respiratory distress" exact="syndrome" post="(ARDS), which is frequently fatal. Patients with comorbidities such"/>
  <result pre="(ARDS), which is frequently fatal. Patients with comorbidities such as" exact="cardiovascular disease," post="diabetes mellitus, hypertension, chronic lung disease, cancer, chronic kidney"/>
  <result pre="is frequently fatal. Patients with comorbidities such as cardiovascular disease," exact="diabetes mellitus," post="hypertension, chronic lung disease, cancer, chronic kidney disease, and"/>
  <result pre="Patients with comorbidities such as cardiovascular disease, diabetes mellitus, hypertension," exact="chronic" post="lung disease, cancer, chronic kidney disease, and obesity (body"/>
  <result pre="with comorbidities such as cardiovascular disease, diabetes mellitus, hypertension, chronic" exact="lung disease," post="cancer, chronic kidney disease, and obesity (body mass index"/>
  <result pre="as cardiovascular disease, diabetes mellitus, hypertension, chronic lung disease, cancer," exact="chronic" post="kidney disease, and obesity (body mass index â‰¥30) and"/>
  <result pre="cardiovascular disease, diabetes mellitus, hypertension, chronic lung disease, cancer, chronic" exact="kidney disease," post="and obesity (body mass index â‰¥30) and ARDS are"/>
  <result pre="diabetes mellitus, hypertension, chronic lung disease, cancer, chronic kidney disease," exact="and obesity" post="(body mass index â‰¥30) and ARDS are at increased"/>
  <result pre="mellitus, hypertension, chronic lung disease, cancer, chronic kidney disease, and" exact="obesity" post="(body mass index â‰¥30) and ARDS are at increased"/>
  <result pre="increased risk of death.14 The available data indicate that the" exact="viral infection" post="can produce an excessive immune reaction known as cytokine"/>
  <result pre="risk of death.14 The available data indicate that the viral" exact="infection" post="can produce an excessive immune reaction known as cytokine"/>
  <result pre="can produce an excessive immune reaction known as cytokine release" exact="syndrome" post="(CRS) or â€œcytokine stormâ€� associated with elevated levels of"/>
  <result pre="C-reactive protein [CRP], ferritin), d-dimer, prothrombin time (PT), troponin and" exact="creatine phosphokinase" post="(CPK), and acute kidney injury.15 Chest CT scans in"/>
  <result pre="d-dimer, prothrombin time (PT), troponin and creatine phosphokinase (CPK), and" exact="acute" post="kidney injury.15 Chest CT scans in patients with COVID-19"/>
  <result pre="in patients with COVID-19 commonly show ground-glass opacification, consistent with" exact="viral pneumonia" post="with abnormalities more likely to be bilateral with a"/>
  <result pre="patients with COVID-19 commonly show ground-glass opacification, consistent with viral" exact="pneumonia" post="with abnormalities more likely to be bilateral with a"/>
  <result pre="consistent with viral pneumonia with abnormalities more likely to be" exact="bilateral" post="with a peripheral distribution involving the lower lobes.16 While"/>
  <result pre="pneumonia with abnormalities more likely to be bilateral with a" exact="peripheral" post="distribution involving the lower lobes.16 While SARS-CoV-2 entry is"/>
  <result pre="likely to be bilateral with a peripheral distribution involving the" exact="lower" post="lobes.16 While SARS-CoV-2 entry is dependent on ACE2 in"/>
  <result pre="relative ACE2 expression is observed in heart, kidney, GIT, and" exact="testes" post="(Gene ID: 59272). The organ- and cell-specific expression of"/>
  <result pre="that it may play a role in the regulation of" exact="cardiovascular" post="and renal function as well as fertility. Surprisingly, the"/>
  <result pre="renal function as well as fertility. Surprisingly, the 2003 SARS-CoV" exact="infection" post="was shown to downregulate the expression of ACE2 in"/>
  <result pre="effect mediated by AT2 with multiple beneficial effects on the" exact="cardiovascular" post="and respiratory system.18 While ACE2 appears to be involved"/>
  <result pre="by AT2 with multiple beneficial effects on the cardiovascular and" exact="respiratory" post="system.18 While ACE2 appears to be involved in the"/>
  <result pre="respiratory system.18 While ACE2 appears to be involved in the" exact="hypertension" post="and respiratory manifestations of severely ill patients, the benefits"/>
  <result pre="While ACE2 appears to be involved in the hypertension and" exact="respiratory" post="manifestations of severely ill patients, the benefits and merits"/>
  <result pre="SARS-CoV-2 patient is still controversial.18 The priming of the S" exact="viral" post="protein by TMPRSS2 is crucial for viral entry where"/>
  <result pre="of the S viral protein by TMPRSS2 is crucial for" exact="viral" post="entry where TMPRSS2 expression is very high in the"/>
  <result pre="they may have a beneficial effect. Potential Drug Targets SARS-CoV-2" exact="viral" post="RNA encodes several proteins that are potentially druggable targets"/>
  <result pre="length negative-strand RNA template used by RdRp to make more" exact="viral" post="genomic RNA. The SARS-CoV-2 genome also contains a number"/>
  <result pre="ORF1b, is proposed to encode nsp12 to nsp16, essential for" exact="viral" post="replication, and ORFs 3a, 3b, 6, 7a, 7b, 8,"/>
  <result pre="accessory proteins1 (Table S2). Figure 1 SARS-CoV-2 encoded proteins. Treating" exact="Viral" post="Infection Immunization against SARS-CoV-2 The development of a manufacturable,"/>
  <result pre="proteins1 (Table S2). Figure 1 SARS-CoV-2 encoded proteins. Treating Viral" exact="Infection" post="Immunization against SARS-CoV-2 The development of a manufacturable, safe,"/>
  <result pre="whole blood may provide instant â€œpassiveâ€� short-lived immunity mainly via" exact="viral" post="neutralization. Antibody dependent therapy, for example targeting the Spike"/>
  <result pre="may provide instant â€œpassiveâ€� short-lived immunity mainly via viral neutralization." exact="Antibody" post="dependent therapy, for example targeting the Spike protein might"/>
  <result pre="SARS-CoV-2 entry and/or replication are urgently needed to mitigate the" exact="symptomatic" post="burden of the disease. Unfortunately, the HIV protease inhibitors"/>
  <result pre="faviprivir.8 Remdesivir was previously tested in humans with Ebola virus" exact="disease" post="and also in animal models of MERS and SARS-CoV.11"/>
  <result pre="are also being considered for the control of SARS-CoV-2 associated" exact="respiratory" post="exacerbations.11 Interestingly, several Janus Kinase (JAK) inhibitors such as"/>
  <result pre="is testing quinolone, macrolide, and Î²-lactam antibiotics against COVID-19 (NCT02735707)." exact="Multiple" post="groups have tested FDA approved drugs in various in"/>
  <result pre="and PLpro are cysteine proteases responsible for the cleavage of" exact="viral" post="polypeptides into functional proteins for virus replication and packaging"/>
  <result pre="Information is available free of charge at https://pubs.acs.org/doi/10.1021/acsinfecdis.0c00224. Tables showing" exact="viral" post="outbreaks since year 2000, different targets expressed in SARS-CoV-2"/>
  <result pre="C.; ZhangY. Z. (2020) A new coronavirus associated with human" exact="respiratory" post="disease in China. Nature579 (7798), 265â€&quot;269. 10.1038/s41586-020-2008-3.32015508 ChanJ. F.;"/>
  <result pre="ZhangY. Z. (2020) A new coronavirus associated with human respiratory" exact="disease" post="in China. Nature579 (7798), 265â€&quot;269. 10.1038/s41586-020-2008-3.32015508 ChanJ. F.; KokK."/>
  <result pre="the 2019 novel human-pathogenic coronavirus isolated from a patient with" exact="atypical pneumonia" post="after visiting Wuhan. Emerging Microbes Infect.9 (1), 221â€&quot;236. 10.1080/22221751.2020.1719902."/>
  <result pre="2019 novel human-pathogenic coronavirus isolated from a patient with atypical" exact="pneumonia" post="after visiting Wuhan. Emerging Microbes Infect.9 (1), 221â€&quot;236. 10.1080/22221751.2020.1719902."/>
  <result pre="potential. Comput. Math Methods Med.2012, 97890110.1155/2012/978901.22649483 (2020) The species severe" exact="acute" post="respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2."/>
  <result pre="Comput. Math Methods Med.2012, 97890110.1155/2012/978901.22649483 (2020) The species severe acute" exact="respiratory" post="syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2. Nat."/>
  <result pre="KuoL.; MastersP. S.; VennemaH.; RottierP. J. (1998) Coronavirus particle assembly:" exact="primary" post="structure requirements of the membrane protein. J. Virol.72 (8),"/>
  <result pre="J. (2020) Characteristics of and important lessons from the coronavirus" exact="disease" post="2019 (COVID-19) outbreak in China: summary of a report"/>
  <result pre="report of 72 314 cases from the Chinese Center for" exact="Disease" post="Control and Prevention. JAMA323 (13), 1239â€&quot;1242. 10.1001/jama.2020.2648. YangX.; YuY.;"/>
  <result pre="Clinical course and outcomes of critically ill patients with SARS-CoV-2" exact="pneumonia" post="in Wuhan, China: a single-centered, retrospective, observational study. Lancet"/>
  <result pre="CaoB. (2020) Clinical course and risk factors for mortality of" exact="adult" post="inpatients with COVID-19 in Wuhan, China: a retrospective cohort"/>
  <result pre="W.; XiaZ. (2020) Review of the clinical characteristics of coronavirus" exact="disease" post="2019 (COVID-19). J. Gen Intern Med.1â€&quot;5. 10.1007/s11606-020-05762-w.31625040 KubaK.; ImaiY.;"/>
  <result pre="ZoghbiA., MotelowJ., HostykJ., and GoldsteinD. (2020) Transcriptional inhibition of host" exact="viral" post="entry proteins as a therapeutic strategy for SARS-CoV-2. Preprints,"/>
  <result pre="der HoekL.; TaguchiF.; MatsuyamaS. (2012) Simultaneous treatment of human bronchial" exact="epithelial" post="cells with serine and cysteine protease inhibitors prevents severe"/>
  <result pre="epithelial cells with serine and cysteine protease inhibitors prevents severe" exact="acute" post="respiratory syndrome coronavirus entry. J. Virol86 (12), 6537â€&quot;6545. 10.1128/JVI.00094-12.22496216"/>
  <result pre="cells with serine and cysteine protease inhibitors prevents severe acute" exact="respiratory" post="syndrome coronavirus entry. J. Virol86 (12), 6537â€&quot;6545. 10.1128/JVI.00094-12.22496216 JeonS.,"/>
  <result pre="with serine and cysteine protease inhibitors prevents severe acute respiratory" exact="syndrome" post="coronavirus entry. J. Virol86 (12), 6537â€&quot;6545. 10.1128/JVI.00094-12.22496216 JeonS., KoM.,"/>
 </snippets>
</snippetsTree>
